G24.01
Drug induced subacute dyskinesia
Clinical Classification Guidelines
Inclusion Terms
- Drug induced blepharospasm
- Drug induced orofacial dyskinesia
- Neuroleptic induced tardive dyskinesia
- Tardive dyskinesia
Medical Intelligence & Overview
Drug-induced subacute dyskinesia is a movement disorder characterized by abnormal, involuntary movements caused by certain medications. This condition includes a variety of movement issues such as blepharospasm (eye twitching or spasms), orofacial dyskinesia (involuntary movements of the face and mouth), and tardive dyskinesia, typically resulting from long-term use of neuroleptic drugs. Recognizing the symptoms early and understanding the potential causes can be crucial for managing this condition effectively.
Causes & Symptoms
Clinical Causes: Long-term use of neuroleptic medications (antipsychotics) Use of medications that affect dopamine pathways in the brain Sudden discontinuation or dosage changes of certain drugs Concurrent use of multiple medications that influence the nervous system
Key Symptoms: Involuntary, repetitive movements of facial muscles, such as grimacing or lip smacking Blepharospasm, which involves involuntary eyelid twitching or spasms Involuntary movements of the tongue, lips, or jaw (orofacial dyskinesia) Facial grimacing, puckering, or grimacing movements Involuntary neck or limb movements Chronic, persistent movement disorders that may worsen over time
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a detailed medical history review, focusing on medication usage, along with a physical examination to observe the movement abnormalities. Healthcare providers may perform neurological assessments and consider ruling out other causes of movement disorders. In some cases, additional tests such as neuroimaging or blood work may be used to exclude other conditions.
Treatment Protocols: Treatment strategies typically aim to reduce or discontinue the offending medication under medical supervision. In some cases, switching to alternative drugs with fewer neurological side effects may be recommended. Medications such as tetrabenazine or benzodiazepines might be prescribed to help manage symptoms. Additionally, physical and occupational therapy can assist in improving motor control and quality of life. Regular monitoring is important to prevent the worsening of symptoms.
Clinical Advice & FAQs
Billing Guidance
Is G24.01 a billable ICD-10 code?
Yes, G24.01 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G24.01?
Clinical documentation must specify the nature of Drug induced subacute dyskinesia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference